Market Overview:
MarkNtel Advisors has released a new report that highlights the strong growth trajectory of the Hepatocellular Carcinoma (HCC) Market, The Global Hepatocellular Carcinoma (HCC) Market is projected to grow at a CAGR of around 10.20% during the forecast period, i.e., 2022-27. Various factors are attributed to the growth of the market like growth in automobile production, growing focus on lightweight & sustainable materials, rising demand for luxury & customized interiors, increasing focus on safety standards, and the adoption of Advanced Driver Assistance Systems (ADAS). The report provides valuable insights into the drivers, trends, and challenges shaping the future of the Hepatocellular Carcinoma (HCC) Market. It offers an in-depth look at the key players, geographical performance, and the segments leading the charge in market share.
Industry Outlook & Forecasts:
- Forecast Period: 2022-2027
- CAGR (2022-2027): 10.20%
Key Perks: “In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecasts for the years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.”
Request for a Free PDF Sample of the Report – https://www.marknteladvisors.com/query/request-sample/hepatocellular-carcinoma-hcc-market.html
Global Hepatocellular Carcinoma (HCC) Market Segmentation Breakdown:
The Hepatocellular Carcinoma (HCC) Market explores the industry by emphasizing the growth parameters and categorizes including geographical segmentation, to offer a comprehensive understanding of the market dynamic. The further bifurcations are as follows:
- By Diagnosis
- Blood Tests
- AFP (Alfa-Fetoprotein)
- LFT (Liver Function Test)
- Hepatic Angiography
- Liver Biopsy
- Laparoscopy
- Others (MRI, CT scan, etc.)
Of all HCC diagnoses, blood tests are the most commonly used laboratory tests owing to their accuracy & cost-efficiency.
- By Treatment
- Chemotherapy
- Cisplatin
- Gemcitabine (Gemzar)
- Oxaliplatin (Eloxatin)
- Doxorubicin (pegylated liposomal doxorubicin)
- 5-fluorouracil (5-FU)
- Immunotherapy
- Atezolizumab (Tecentriq)
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Ipilimumab (Yervoy)
- Surgery
- Hepatectomy
- Liver Transplant
- Radiation Therapy
- Targeted Therapy
- Kinase Inhibitors
- Sorafenib
- Lenvatinib
- Regorafenib (Stivarga)
- Cabozantinib (Cabometyx)
- Monoclonal Antibodies
- Bevacizumab (Avastin)
- Ramucirumab (Cyramza)
Of all treatments, targeted therapy drugs like Sorafenib & Lenvatinib (kinase inhibitors) led the Global Hepatocellular Carcinoma (HCC) Market in previous years.
- By End-User
- Hospitals
- Cancer Centers
- Others (Ambulatory Surgery Centers, etc.)
Geographical Growth Insights:
By Region
- North America
- South America
- Europe
- Middle East & Africa
- Asia-Pacific
Of all regions globally, North America holds a significant share in the Hepatocellular Carcinoma (HCC) Market.
MarkNtel Advisors Highlights Key Market Drivers for Hepatocellular Carcinoma (HCC) Market:
Substantial R&D Investments by Leading Pharma & Biotech Companies Worldwide
The key companies in the biotechnology & pharmaceutical ecosystem are massively investing in R&D activities associated with discovering & implementing more efficient & accurate diagnoses & treatments for hepatocellular cancer. As a result of the rising patient pool of HCC, there's a burgeoning demand for oncology drugs, coupled with increasing strategic collaborations to expand the product portfolio, which, in turn, would drive the Global Hepatocellular Carcinoma (HCC) Market during 2022-27.
A Comprehensive Analysis of Leading Companies in Global Hepatocellular Carcinoma (HCC) Market
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- BeiGene
- Bristol Myers Squibb
- Eisai Co., Ltd.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
Explore More About This Research Report @ https://www.marknteladvisors.com/research-library/hepatocellular-carcinoma-hcc-market.html
“Report Delivery Format: Market research reports from MarkNtel Advisors are available in PDF, Excel, and PowerPoint formats. Once payment is successfully processed, the report will be delivered to your email address within 24 hours”
Note: If you need additional information not included in the report, we can customize it to suit your requirements.
Contact Our Analysts for Brochure Requests, Customization, or Any Pre-Purchase Inquiries: https://www.marknteladvisors.com/query/request-customization/hepatocellular-carcinoma-hcc-market.html
About Us –
MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.
We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.
More Research Studies:
- The Global Tire (Tyre) Market size is valued at around USD 232Billion in 2023 and is estimated to grow at a CAGR of about 4.11% during the forecast period 2024-29. MRF Limited CEAT Limited JK Tire, and Bridgestone are top tire companies.
- Switchgear Market size was valued at USD44Billion in 2023 and is estimated to grow at a CAGR of around 6.3% during the forecast period 2024-30.
- Explore the Global Flare Monitoring Market, valued at USD3Billion in 2023 and projected to reach USD 2.5 Billion by 2030, growing at a CAGR of 10.1%. Learn about trends, drivers, and regional insights.
Media Contact:
Company Name: MarkNtel Advisors
Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
Email: sales@marknteladvisors.com
Phone: +1 628 895 8081, +91 120 4278433
Website: www.marknteladvisors.com/